)

Longeveron (LGVN) investor relations material
Longeveron Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Achieved full enrollment for pivotal phase 2b HLHS trial (ELPIS II), with top-line results expected Q3 2026 and BLA submission targeted for late 2026, pending positive results.
Advanced stem cell pipeline for HLHS, Alzheimer's, and pediatric dilated cardiomyopathy, including FDA IND approval for pediatric DCM and positive regulatory progress for Alzheimer's.
Received FDA Orphan Drug, Fast Track, Rare Pediatric Disease, and RMAT designations for HLHS and Alzheimer's programs.
Discontinued Japan Aging-related Frailty trial to focus resources on core programs.
Ongoing efforts to secure additional financing and strategic partnerships, with substantial doubt about ability to continue as a going concern without new capital.
Financial highlights
Revenue for the first half of 2025 was $0.7M, down 31–32% year-over-year, mainly due to lower demand for clinical trials and contract manufacturing.
Gross profit for the first half of 2025 was $0.4M, a 37% decrease from the prior year.
General and administrative expenses rose 28% to $5.5M; R&D expenses increased 39% to $5.5M, driven by personnel and BLA readiness costs.
Net loss for the first half of 2025 was $10.0M, up 34% year-over-year.
Cash and equivalents stood at $10.2–$10.3M as of June 30, 2025; $5M raised in August public offering, with up to $12.5M more possible from warrants.
Outlook and guidance
Existing cash expected to fund operations into Q1 2026; additional capital required to continue beyond that period.
Operating expenses and capital requirements projected to rise through 2025 and 2026 due to BLA and manufacturing readiness.
BLA filing for HLHS targeted for late 2026, contingent on ELPIS II results; pivotal phase 2 trial for pediatric DCM anticipated to begin in H1 2026, subject to financing.
Seeking partnerships for Alzheimer's program and pursuing non-dilutive funding.
Next Longeveron earnings date

Next Longeveron earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage